Issue link: https://www.e-digitaleditions.com/i/1526741
8 BioPharm International ® Emerging Therapies eBook September 2024 www.biopharminternational.com Deck_ Deck_ Deck_ Deck_ Deck_ Deck_ Deck_ Deck_ Deck_ Deck_ Deck_ Deck_ Deck_ Deck_ Deck_ Deck_ Deck_ Deck_ Deck_ Deck_ JCG - STOCK.ADOBE.COM C ell line development (CLD) plays a pivot- al role in the production of biotherapeutic molecules. The primary goal during CLD is to generate and identify the most stable cell lines capable of robust production of high-quality therapeutic molecules. To achieve this, screening for both product quality and productivity is essential. Identifying and optimizing stable high-yield cell lines early contributes to accelerating the entire drug development process and the success of the pipeline. In add it ion to classica l biologic d r ugs such as monoclona l a nt ibodies (m Abs), new t herapeut ic modalities are being developed at a rapid pace. These include bi-, tri-, and multi-specific antibodies, anti- body-drug conjugates (ADCs), and f usion proteins such as bispecific T-cell engagers (BiTEs) and pep- tide-Fc proteins or peptibodies (1,2). The increasing complexit y and diversit y of these new modalities require innovative analytical approaches that inte- grate technologies such as capillary electrophoresis (CE) and mass spectrometry (MS). Integrated CE–MS technologies provide the necessary sensitivity, accu- racy, and precision to monitor key product quality attributes (PQAs), detect data inconsistencies, and thus characterize, screen, and select optimal cell line clones early in the CLD process. Managing data inconsistencies in CLD Given the vast number of potential clones entering the development pipeline, methods to rapidly prioritize candidates are crucial. These methods must be able to quickly and precisely assess the critical quality attri- butes (CQAs) of the protein products to narrow down the best candidates. Chemical post-translational mod- ifications (PTMs), such as glycosylation, deamidation, and oxidation, are considered CQAs as they often re- sult in charge variants that affect the product's stabil- ity, efficacy, potency, and safety. As such, PTMs must be characterized and controlled throughout the drug development pipeline. Ensuring Cell Line Stability for Protein Therapeutics Roxana McCloskey is senior global marketing manager, Protein Therapeutics, and Zoe Zhang is manager, Biopharma Applications; both at SCIEX. Stable cell line development can benefit from applying integrated analytical technologies.